Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS

被引:28
|
作者
Berscheid, Anne [1 ]
Francois, Patrice [2 ,3 ]
Strittmatter, Axel [4 ]
Gottschalk, Gerhard [4 ]
Schrenzel, Jacques [2 ,3 ]
Sass, Peter [5 ]
Bierbaum, Gabriele [1 ]
机构
[1] Univ Bonn, IMMIP, Bonn, Germany
[2] Univ Hosp Geneva, Infect Dis Serv, Genom Res Lab, Geneva, Switzerland
[3] Univ Geneva, Geneva, Switzerland
[4] Univ Gottingen, Inst Microbiol & Genet, D-37073 Gottingen, Germany
[5] Univ Dusseldorf, Inst Pharmaceut Biol, Dusseldorf, Germany
关键词
glycopeptides; teicoplanin; daptomycin; antibiotic resistance; two-component regulatory systems; WALL STRESS STIMULON; CELL-WALL; DAPTOMYCIN SUSCEPTIBILITY; DECREASED SUSCEPTIBILITY; GLYCOPEPTIDE-RESISTANCE; REDUCED SUSCEPTIBILITY; 2-COMPONENT SYSTEM; MPRF; EXPRESSION; MECHANISMS;
D O I
10.1093/jac/dku297
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Staphylococcus aureus is a notorious bacterial pathogen and antibiotic-resistant isolates complicate current treatment strategies. We characterized S. aureus VC40, a laboratory mutant that shows full resistance to glycopeptides (vancomycin and teicoplanin MICs a parts per thousand yen32 mg/L) and daptomycin (MICaEuroS=aEuroS4 mg/L), to gain deeper insights into the underlying resistance mechanisms. Genomics and transcriptomics were performed to characterize changes that might contribute to development of resistance. The mutations in vraS were reconstituted into a closely related parental background. In addition, antimicrobial susceptibility testing, growth analyses, transmission electron microscopy, lysostaphin-induced lysis and autolysis assays were performed to characterize the phenotype of resistant strains. Genome sequencing of strain VC40 revealed 79 mutations in 75 gene loci including genes encoding the histidine kinases VraS and WalK that control cell envelope-related processes. Transcriptomics indicated the increased expression of their respective regulons. Although not reaching the measured MIC for VC40, reconstitution of the L114S and D242G exchanges in VraS(VC40) into the susceptible parental background (S. aureus NCTC 8325) resulted in increased resistance to glycopeptides and daptomycin. The expression of VraS(VC40) led to increased transcription of the cell wall stress stimulon, a thickened cell wall, a decreased growth rate, reduced autolytic activity and increased resistance to lysostaphin-induced lysis in the generated mutant. We show that a double mutation of a single gene locus, namely vraS, is sufficient to convert the vancomycin-susceptible strain S. aureus NCTC 8325 into a vancomycin-intermediate S. aureus.
引用
收藏
页码:3190 / 3198
页数:9
相关论文
共 50 条
  • [21] A Novel δ-Hemolysis Screening Method for Detecting Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate S-aureus
    Cafiso, V.
    Bertuccio, T.
    Spina, D.
    Purrello, S.
    Blandino, G.
    Stefani, Stefania
    JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (05) : 1742 - 1744
  • [22] Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus
    Lu, JJ
    Lee, SY
    Hwa, SY
    Yang, AH
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 4156 - 4158
  • [23] Aortic Root Abscess with Aorta to Right Atrium Fistula due to Vancomycin-Intermediate Staphylococcus aureus (VISA)
    Hankinson, Stephen J.
    Sultanik, Elliot A.
    Ramani, Gautam V.
    CASE REPORTS IN CARDIOLOGY, 2019, 2019
  • [24] Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem
    Katayama, Yuki
    Murakami-Kuroda, Hiroko
    Cui, Longzhu
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) : 3190 - 3196
  • [25] Survival of vancomycin-intermediate Staphylococcus aureus on hospital surfaces
    Zarpellon, M. N.
    Gales, A. C.
    Sasaki, A. L.
    Selhorst, G. J.
    Menegucci, T. C.
    Cardoso, C. L.
    Garcia, L. B.
    Tognim, M. C. B.
    JOURNAL OF HOSPITAL INFECTION, 2015, 90 (04) : 347 - 350
  • [26] Biofilms: A developmental niche for vancomycin-intermediate Staphylococcus aureus
    Chapman, Jenelle E.
    George, Shilpa E.
    Wolz, Christiane
    Olson, Michael E.
    INFECTION GENETICS AND EVOLUTION, 2024, 117
  • [27] Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphylococcus aureus
    Bakar, Nur Salwani
    Zin, Noraziah Mohamad
    Basri, Dayang Fredalina
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 25 (03) : 633 - 638
  • [28] Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure
    Kelley, Peter G.
    Gao, Wei
    Ward, Peter B.
    Howden, Benjamin P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) : 1057 - 1060
  • [29] DIFFERENTIAL INFLAMMATORY RESPONSES IN MACROPHAGES BY VANCOMYCIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS AND VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS
    Lee, H. -S.
    Kuo, T. -Y.
    INFLAMMATION RESEARCH, 2011, 60 : 159 - 159
  • [30] Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis
    Julian, Kathleen
    Kosowska-Shick, Klaudia
    Whitener, Cynthia
    Roos, Martin
    Labischinski, Harald
    Rubio, Aileen
    Parent, Leslie
    Ednie, Lois
    Koeth, Laura
    Bogdanovich, Tatiana
    Appelbaum, Peter C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (09) : 3445 - 3448